Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | GPR3 | P46089 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28780452 | 0.91 | EPHX2 (0.50) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL255560 | 0.88 | GPR3 (0.52) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL13863723 | 0.88 | MAPT (0.48) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL513525 | 0.86 | MAPT (0.52) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL5073 | 0.86 | TDP1 (0.50) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL97453 | 0.86 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL7007579 | 0.86 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL221511 | 0.86 | MAPT (0.52) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL2097243 | 0.86 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL15372299 | 0.86 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106750301-B | Sulfonated polyether sulfone copolymer containing pyridine groups, preparation method and application | 中国工程物理研究院化工材料研究所 | 2019-03-22 | — | — | CN | claimed |
| CN-106750191-B | Sulfonated polyether ketone copolymers of the main chain containing pyridine groups, preparation method and application | 中国工程物理研究院化工材料研究所 | 2018-10-26 | — | — | CN | claimed |
| CN-105601906-B | Sulfonated poly aryl ether ketone cross linking membrane of sulfur-bearing ehter bond and preparation method thereof | 中国工程物理研究院化工材料研究所 | 2018-02-16 | — | — | CN | claimed |
| CN-106750301-A | Sulfonated polyether sulfone copolymer containing pyridine groups, preparation method and application | 中国工程物理研究院化工材料研究所 | 2017-05-31 | — | — | CN | claimed |
| CN-106750191-A | Sulfonated polyether ketone copolymers, preparation method and application of the main chain containing pyridine groups | 中国工程物理研究院化工材料研究所 | 2017-05-31 | — | — | CN | claimed |
| CN-105601906-A | Sulfonated poly aryl ether ketone cross-linking membrane containing thioether keys and preparing method thereof | INST CHEMICAL MAT CHINA ACAD ENG PHYSICS | 2016-05-25 | — | — | CN | claimed |
| US-6677379-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATMENT OF CORONARY ARTERY DISEASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | claimed |
| US-20260088362-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | MURATA MANUFACTURING CO (JP) | 2026-03-26 | — | — | US | disclosed |
| WO-2025013623-A1 | ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | 株式会社村田製作所 | 2025-01-16 | — | — | WO | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-114287077-A | Nonaqueous electrolyte solution, battery pack, and method for producing battery pack | 旭化成株式会社 | 2022-04-05 | — | — | CN | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| EP-0567848-B1 | Process for the alpha-chlorination of arylethern | BAYER AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| US-5440051-A | Halogenating by metering into reaction vessel at the same time as chlorine in presence of solvent or absence of solvent to form a chemical intermediates for fungicides or insecticides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0567848-A1 | Process for the alpha-chlorination of arylethern | BAYER AG (DE) | 1993-11-03 | — | — | EP | disclosed |
| EP-0130876-B1 | PROCESS FOR THE SIMULTANEOUS HALOGENATION AND FLUORINATION OF AROMATIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1988-04-20 | — | — | EP | disclosed |
| US-4575571-A | HALOGEN IN LIQUID HYDROGEN FLUORIDE | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1986-03-11 | — | — | US | disclosed |
| EP-0113625-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYLATED BENZENIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1985-07-10 | — | — | EP | disclosed |
| US-4157344-A | REACTING PHENOLS WITH A PERHALOMETHANE AND HYDROGEN FLUORIDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260088362-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | HCN2, HCN1, PEF1 | MAPT 3368/4885EPHX2 1316/4885GPR3 4124/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | MAPT 268/4885EPHX2 2810/4885GPR3 2588/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | MAPT 519/4885EPHX2 3205/4885GPR3 2010/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | MAPT 519/4885EPHX2 3205/4885GPR3 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.